Ritter Pharmaceuticals Issued Method of Use Patent for RP-G28
2016年6月28日 - 10:15PM
Marketwired
Ritter Pharmaceuticals Issued Method of Use Patent for
RP-G28
Patent Covers Methods for Treating Symptoms Associated With
Lactose Intolerance and Improving Gastrointestinal Health
LOS ANGELES, CA-(Marketwired - Jun 28, 2016) - Ritter
Pharmaceuticals, Inc. (NASDAQ: RTTR) ("Ritter Pharmaceuticals" or
the "Company"), a pharmaceutical company developing novel
therapeutic products that modulate the human gut microbiome to
treat gastrointestinal diseases, today announced that it recently
has been issued U.S. Patent No. 9,370,532 by the U.S. Patent &
Trademark Office.
U.S. Patent No. 9,370,532 covers methods for treating symptoms
associated with lactose intolerance and for overall improvement in
gastrointestinal health. Subject to the payment of maintenance
fees, this patent will remain in force until 2030.
"We are excited to have received additional patent protection
related to RP-G28, our treatment for lactose intolerance which has
the potential to be the first FDA-approved treatment for this
indication," commented Michael D. Step, Chief Executive Officer of
Ritter Pharmaceuticals. "As announced earlier this year, we gained
patent protection for the manufacturing and composition of RP-G28.
This new patent will provide us with further protection as we work
to bring a safe and effective treatment to patients suffering from
lactose intolerance and to achieve long-term value for the company
and its shareholders."
About Ritter PharmaceuticalsRitter Pharmaceuticals, Inc.
develops novel therapeutic products that modulate the human gut
microbiome to treat gastrointestinal diseases. The Company is
advancing human gut health research by exploring the metabolic
capacity of gut microbiota, and translating the functionality of
these microbiome modulators into safe and effective applications.
Their lead drug candidate, RP-G28, has the potential to become the
first FDA-approved drug for lactose intolerance, a condition that
affects more than one billion people worldwide.
Forward-Looking StatementsRitter Pharmaceuticals, Inc. develops
novel therapeutic products that modulate the human gut microbiome
to treat gastrointestinal diseases. The Company is advancing human
gut health research by exploring the metabolic capacity of gut
microbiota, and translating the functionality of these microbiome
modulators into safe and effective applications. Their lead drug
candidate, RP-G28, has the potential to become the first
FDA-approved drug for lactose intolerance, a condition that affects
more than one billion people worldwide.
Contact Information
ContactsInvestor Contact:David Burkedburke@theruthgroup.com(646)
536-7009Media Contact:Chris
Hippolytechippolyte@theruthgroup.com(646) 536-7023
Ritter Pharmaceuticals (NASDAQ:RTTR)
過去 株価チャート
から 6 2024 まで 7 2024
Ritter Pharmaceuticals (NASDAQ:RTTR)
過去 株価チャート
から 7 2023 まで 7 2024